ATI RN
WGU Pathophysiology Final Exam
1. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?
- A. It stimulates the formation of new bone.
- B. It decreases bone resorption and increases bone density.
- C. It increases calcium absorption in the intestines.
- D. It increases the excretion of calcium through the kidneys.
Correct answer: B
Rationale: The correct answer is B. Raloxifene works by decreasing bone resorption and increasing bone density, which helps in the prevention and treatment of osteoporosis. Choice A is incorrect as raloxifene does not directly stimulate the formation of new bone. Choice C is incorrect because raloxifene does not primarily affect calcium absorption in the intestines. Choice D is incorrect as raloxifene does not increase the excretion of calcium through the kidneys.
2. A male patient receiving androgen therapy is concerned about prostate cancer. What should the nurse explain about the risks associated with this therapy?
- A. Finasteride has been shown to reduce the risk of developing prostate cancer.
- B. Finasteride has no impact on the risk of developing prostate cancer.
- C. Finasteride may increase the risk of developing prostate cancer.
- D. Finasteride has no effect on the risk of prostate cancer.
Correct answer: A
Rationale: The correct answer is A. Finasteride, a type of androgen therapy, has been shown to reduce the risk of developing prostate cancer. It works by shrinking the prostate gland, which can help lower the risk of developing prostate cancer. However, while it may reduce the risk, regular screening is still recommended to monitor for any potential issues. Choice B is incorrect because finasteride does have an impact on reducing the risk of prostate cancer. Choice C is incorrect as finasteride is not known to increase the risk of developing prostate cancer. Choice D is incorrect as finasteride does have an effect on reducing the risk of prostate cancer.
3. A male patient is receiving androgen therapy for hypogonadism. What adverse effect should the nurse monitor for during this therapy?
- A. Increased risk of bone fractures
- B. Increased risk of cardiovascular events
- C. Increased risk of liver dysfunction
- D. Increased risk of prostate cancer
Correct answer: B
Rationale: The correct answer is B: Increased risk of cardiovascular events. Androgen therapy can lead to an increased risk of cardiovascular events like heart attacks and strokes, especially in older patients. Monitoring for signs and symptoms of cardiovascular issues is essential during this therapy. Choices A, C, and D are incorrect because androgen therapy is not typically associated with an increased risk of bone fractures, liver dysfunction, or prostate cancer.
4. A patient is being treated with raloxifene (Evista) for osteoporosis. What should the nurse teach the patient about this medication?
- A. It is used as a selective estrogen receptor modulator to prevent bone loss.
- B. It works by decreasing bone formation and increasing bone resorption.
- C. It should be taken with food to reduce gastrointestinal side effects.
- D. It may cause weight gain and fluid retention.
Correct answer: C
Rationale: The correct answer is C. Raloxifene is a selective estrogen receptor modulator (SERM) used to prevent bone loss. It should be taken with food to reduce gastrointestinal side effects, not on an empty stomach. Choices A and B are incorrect because raloxifene is indeed a SERM that prevents bone loss, but it does not directly work by increasing bone formation or decreasing bone resorption. Choice D is incorrect as weight gain and fluid retention are not common side effects of raloxifene.
5. Canola oil produced from genetically modified canola plants altered to be herbicide-resistant is an example of a:
- A. pesticide-free food.
- B. saturated fat food.
- C. genetically modified food.
- D. product that is pure.
Correct answer: C
Rationale: The correct answer is 'genetically modified food.' Canola oil derived from genetically modified canola plants falls into this category because the plant's genome has been altered to exhibit herbicide resistance. This genetic modification makes it a genetically modified food. Choice A, 'pesticide-free food,' is incorrect as the genetic modification is to resist herbicides, not pesticides. Choice B, 'saturated fat food,' is incorrect as it does not accurately describe the genetic modification of the canola plants. Choice D, 'product that is pure,' is too vague and does not address the genetic modification aspect of the canola plants.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access